Expression And Sense Of Her-2 And CD44 In Malignant Brain Tumors

The diagnosis and treatment of malignant brain tumors in the central nervous system diseases are difficulty all the way, the effect of clinical treatment is not very well. At present the medical workers refine original treatments constantly and explore new treatments actively. Biological targeted therapy as a new treatment method is expected to become effective method to malignant tumors. the premise to carry out the targeting therapy research is having effective biological targets. Human epidermal growth factor receptor type 2 (Her-2) is a cancer gene receptor, in a variety of malignant tumor, to express. CD44 is a sort of cell surface adhesion molecules. Now it are, in variety of tumor, the research and clinical diagnostic markers.Objective To detect and analyze human epidermal growth factor receptor(HER-2) and CD44 in different malignant brain tumors, and to evaluate their prognostic significance.Methods Using immunohistochemistry and indirect immunofluorescence to detect the expression of Her-2 and CD44 in malignant brain tumors and analyzing the experimental data. The specimens contain 10 normal brain tumors and 120 malignant brain tumors that are glioblastoma, gliosarcoma, medulloblastoma and anaplastic oligodendroglioma.Results The positive rate of Her-2 in the glioblastoma, gliosarcoma, medulloblastoma, and anaplastic oligodendroglioma respectively were 80.0%, 73.3%, 66.7% and 33.3%. The positive rate of CD44 in these four tumors respectively were 86.7%, 80.0%, 90.0%, 73.3%. The expression of Her-2 in normal brain tissue was none, but CD44 was 20.0% . The expression in malignant brain tumor had no correlation between Her-2 and CD44 (P>0.05), but they both correlate with tumor prognosis. Conclusions The expressions of Her-2 were not same in malignant brain tumors, the expressions of CD44 were generally high. No correlation between Her-2 and CD44, but they have synergistic effect with the prognosis of tumors. Her-2 and CD44 are expected to be combined target site for target therapies of brain tumor. They will play an important role in the brain tumor diagnosis and treatment.